Method for stratifying subjects

Abstract

To provide a method of stratifying subjects.SOLUTION: A method of stratifying subjects is provided, comprising classifying a subject into a group with or without plaque adhesion, and comparing an antibody titer against periodontal pathogens in a blood sample collected from the subject with a reference value and classifying the subject into a group with the antibody titer equal to or greater than the reference value or a group with the antibody titer less than the reference value.SELECTED DRAWING: None

Description

Technical Field

[0001] The present disclosure relates to a method for stratifying subjects and the like. Specifically, it relates to a method for stratifying subjects for determining an oral hygiene product or an oral hygiene method. Further, the present disclosure relates to an oral hygiene product or the like for a subject stratified by the above method.

Background Art

[0002] Periodontal disease is an inflammatory disease caused by the infection of periodontal pathogenic bacteria in the periodontal tissue, and is roughly classified into gingivitis and periodontitis according to the degree of progression. Plaque caused by poor oral hygiene is considered to be one of the causes of periodontal disease, and since gingivitis occurs when oral hygiene actions are stopped, the importance of oral hygiene actions for removing plaque is shown.

[0003] In addition, it is considered important to select appropriate oral care according to the situation of the oral environment, such as the presence or absence and degree of periodontal disease, in order to improve and keep the oral environment clean.

Prior Art Documents

Patent Documents

[0004]

Patent Document 1

Summary of the Invention

Problems to be Solved by the Invention

[0005] The progression from gingivitis to periodontitis is thought to occur as an extension of the persistence of gingival inflammation due to plaque attachment. However, since oral bacteria such as periodontal pathogenic bacteria and biological factors (systemic diseases) are involved in a complex manner, it is difficult to evaluate periodontal disease only by the presence or absence of plaque attachment, and there are problems in screening in the absence of a dental expert.

[0006] Also, for example, when a subject suffering from periodontal disease performs thorough toothbrushing immediately before an oral examination, the plaque cleaning status will be good during the examination, but the degree of periodontal disease is unlikely to be improved by such toothbrushing. As can be understood from this, it is often difficult to evaluate periodontal disease based only on the presence or absence of plaque adhesion, and thus there is a demand for the development of a simple diagnostic method for periodontal disease or the like (Patent Document 1).

[0007] An object of the present disclosure is to provide a method for stratifying subjects. Another object of the present disclosure is also to provide a method for stratifying subjects in order to determine an oral hygiene product or an oral hygiene method suitable for the presence or degree of periodontal disease.

Means for Solving the Problems

[0008] The present inventors have found that by classifying subjects by combining not only the presence or absence of plaque but also the blood antibody titer (infection degree) against periodontal pathogens, it is possible to predict the presence or degree of periodontal disease, and have further made improvements.

[0009] The present disclosure includes, for example, the subject matter described in the following items. Item 1. Classifying a subject into a group with plaque adhesion or a group without plaque adhesion, and Comparing the antibody titer against periodontal pathogens in a blood sample collected from the subject with a reference value, and classifying the subject into a group equal to or higher than the reference value or a group lower than the reference value including A method for stratifying a subject. Item 2. Furthermore, the method according to Item 1, including comparing the age of the subject with a reference value and classifying the subject into a group equal to or higher than the reference value or a group lower than the reference value. Item 3. The method according to Item 1 or 2, characterized in that it is used for determining an oral hygiene product or an oral hygiene method. Item 4. In the method according to any one of Items 1 to 3, Oral hygiene products for subjects classified into the group with plaque adhesion. Item 4-1. In the method according to any one of Items 1 to 3, having plaque adhesion and oral hygiene products for subjects classified into the group having antibody titer equal to or higher than the reference value. Item 4-2. In the method according to any one of Items 1 to 3, having plaque adhesion and oral hygiene products for subjects classified into the group having antibody titer lower than the reference value. Item 4-3. In the method according to Item 2 or 3, having plaque adhesion, having antibody titer equal to or higher than the reference value, and oral hygiene products for subjects classified into the group having age equal to or higher than the reference value. Item 4-4. In the method according to Item 2 or 3, having plaque adhesion, having antibody titer equal to or higher than the reference value, and oral hygiene products for subjects classified into the group having age lower than the reference value. Item 5. In the method according to any one of Items 1 to 3, having no plaque adhesion and oral hygiene products for subjects classified into the group having antibody titer equal to or higher than the reference value. Item 6. In the method according to any one of Items 1 to 3, having no plaque adhesion and oral hygiene products for subjects classified into the group having antibody titer lower than the reference value. Item 7. In the method according to Item 2 or 3, having no plaque adhesion, having antibody titer equal to or higher than the reference value, and oral hygiene products for subjects classified into the group having age equal to or higher than the reference value. Item 8. In the method according to item 2 or 3, without the attachment of the plaque, wherein the antibody titer is equal to or higher than the reference value, and an oral hygiene product for a subject classified into a group in which the age is less than the reference value. Item 9. A method for measuring the presence or absence or degree of periodontal disease in a subject, using the presence or absence of plaque attachment in the subject and the antibody titer against periodontal pathogenic bacteria in a blood sample collected from the subject as indicators, stratifying the subject based on the presence or absence of plaque attachment and the antibody titer comprising the method.

Advantages of the Invention

[0010] A method for stratifying a subject is provided. Also provided is an oral hygiene product for the stratified subject.

Brief Description of the Drawings

[0011]

Figure 1

Modes for Carrying Out the Invention

[0012] Hereinafter, each embodiment included in the present disclosure will be described in more detail. The present disclosure includes a method for stratifying a subject. In this specification, the stratifying method may be referred to as "the stratifying method of the present disclosure".

[0013] In this specification, "stratifying" means classifying and extracting a subject into several groups.

[0014] The stratifying method of the present disclosure includes classifying a subject into a group with plaque attachment or a group without plaque attachment. The stratifying method of the present disclosure may include confirming the presence or absence of plaque attachment.

[0015] The subject is not particularly limited as long as it is a human. For example, it may be a healthy person, a human suffering from periodontal disease (periodontal disease patient), or a human suspected of having periodontal disease.

[0016] In this specification, "plaque" means a mass of bacteria adhering to the surface of teeth. Plaque is sometimes referred to as dental plaque.

[0017] The method for confirming the presence or absence of plaque attachment is not particularly limited, and known methods can be adopted. For example, a method of determining the presence or absence of plaque attachment by rubbing the tooth surface with the tip of a periodontal probe or a dental explorer, a method of determining the presence or absence of plaque attachment by staining the tooth surface using a plaque staining solution, a method of determining the presence or absence of plaque attachment by image diagnosis, a method of detecting plaque by a sensor, etc. can be mentioned. In addition, since the attachment of plaque occurs as a result of insufficient oral hygiene, it is already known that there is a relationship with the number of toothbrushing times and the use of interdental cleaning tools, and that gingival bleeding occurs when plaque attachment continues. Therefore, an oral hygiene behavior questionnaire (survey) or an examination for examining bleeding (occult blood) from the gingiva can also be used as a substitute for plaque attachment.

[0018] The teeth for which the presence or absence of plaque attachment is to be confirmed may be, for example, all teeth or target teeth. The target teeth may be, for example, a total of six teeth including the upper right 6, upper right 1, upper left 6, lower right 6, lower left 1, and lower left 6. The said numbers correspond to the numbers shown in FIG. 1. Also, teeth that can be photographed with a smartphone or the like (mainly the anterior teeth), or teeth that can be photographed with an intraoral camera may be used.

[0019] When plaque adhesion is not observed or is below the detection limit by the method described above, it is classified into the group without plaque adhesion. Otherwise, it is classified into the group with plaque adhesion. Also, as shown in the examples described later, when evaluating the presence or absence of plaque by Plaque Index (PlI), if the average value of the measured PlI is, for example, less than 0.5 (preferably less than 0.25, more preferably 0), it is classified into the group without plaque adhesion. If it is 0.5 or more (preferably 0.25 or more, more preferably greater than 0), it is classified into the group with plaque adhesion.

[0020] The stratification method of the present disclosure includes comparing the antibody titer against periodontal pathogens in a blood sample collected from the subject with a reference value and classifying the subject into a group with a value equal to or higher than the reference value or a group with a value lower than the reference value. The stratification method of the present disclosure may include measuring the antibody titer against periodontal pathogens in a blood sample collected from the subject.

[0021] The blood sample is not particularly limited as long as it is a sample derived from blood collected from the subject. For example, it may be whole blood or a blood isolate (e.g., serum, plasma, etc.). Among them, plasma or serum is preferred, and serum is more preferred. Note that the method and conditions for storing the blood sample collected from the subject are not particularly limited and can be carried out according to conventional methods.

[0022] The method for collecting a blood sample from the subject is not particularly limited and may be carried out according to a conventional method. When using serum or plasma as the blood sample, it is preferable to use a vacuum blood collection tube containing a serum or plasma separator from the viewpoints of ease of handling and infection prevention. Also, the collected blood sample may be used as it is, or after being freeze-dried and stored, the freeze-dried product may be dissolved in an appropriate solvent described later and used. Alternatively, the collected blood sample may be stored frozen as it is, or after being dissolved in an appropriate solvent described later and then stored frozen, it may be thawed and used at the time of use.

[0023] Examples of the solvent for dissolving the blood sample include physiological saline, PBS, phosphate buffer, Tris buffer, borate buffer, Good Buffer, and the like. These solvents may contain protein stabilizers such as those containing casein, skim milk, bovine serum albumin (BSA), gelatin, blood protein or plant protein as active ingredients, normal animal blood components such as mouse, rabbit, goat, fetal bovine, etc., normal human serum components, etc.; various preservatives; surfactants; enzyme activators such as salts of metals such as zinc and magnesium.

[0024] As a method for measuring the antibody titer against periodontal pathogenic bacteria, for example, an antibody (such as IgG antibody, IgA antibody, IgM antibody, etc.) against periodontal pathogenic bacteria present in a blood sample, which is generated by contacting a polypeptide having antigenicity (reacting with an antibody against periodontal pathogenic bacteria) with the blood sample, and the antigen-antibody reaction product (a complex containing the antibody and the polypeptide) between the polypeptide and the antibody can be detected.

[0025] In this specification, "having antigenicity" means reacting with an antibody against periodontal pathogenic bacteria. Examples of the antibody include immunoglobulin antibodies such as IgG antibody, IgM antibody, and IgA antibody, and any of the immunoglobulin antibodies may react with the antigen. Among them, IgG antibody is preferred.

[0026] Antigenicity can be evaluated by the ELISA method. More specifically, when a polypeptide for evaluating antigenicity is used as an antigen and a positive serum of a periodontal disease patient containing an antibody against periodontal pathogenic bacteria is used as a primary antibody, and these antigen-antibody reactions are detected by the ELISA method, the polypeptide is determined to have antigenicity.

[0027] The polypeptide having antigenicity is not particularly limited as long as it reacts with an antibody against periodontal pathogenic bacteria, and known polypeptides can be used. For example, it may be a polypeptide containing the amino acid sequence shown in SEQ ID NO: 1, or a polypeptide consisting of the amino acid sequence shown in SEQ ID NO: 1.

[0028] Polypeptides can be produced using common protein chemical synthesis methods (e.g., liquid phase method and solid phase method) based on the information of the amino acid sequence. In addition, the above-mentioned polypeptides can be produced by genetic engineering techniques using polynucleotides encoding the polypeptides.

[0029] Polypeptides may further contain tags. Examples of tags include peptide tags such as His tag, SBP (Streptavidin Binding Peptide) tag, etc.; polypeptide tags such as GST (Glutathione-S-transferase) tag, MBP (Maltose Binding Protein) tag, etc. Among them, polypeptide tags are preferred, and GST tags are more preferred.

[0030] The method for adding tags is not particularly limited, and conventional methods and reaction conditions can be adopted.

[0031] Polypeptides may further have a labeling substance. Examples of labeling substances include horseradish peroxidase (HRP) derived from wasabi, alkaline phosphatase (ALP), β-D-galactosidase, biotin, gold colloid, latex beads, etc.

[0032] The method for detecting antigen-antibody reaction products is not particularly limited, and conventional methods and reaction conditions can be adopted. For example, a method of contacting the antigen-antibody reaction product with an anti-immunoglobulin (e.g., anti-IgG antibody, etc.) containing a labeling substance to detect the labeling substance, or when the polypeptide contains a labeling substance, a method of detecting the labeling substance, etc. can be mentioned. The method for detecting antigen-antibody reaction products may, if necessary, include, for example, a step of immobilizing the antigen on a solid phase, a washing step, a blocking step, a substrate reaction step, etc. These can adopt conventional methods and reaction conditions.

[0033] As a method for detecting antigen-antibody reactants, immunological methods such as ELISA, FLEIA, CLEIA, dot blot method, and immunochromatography method are preferably used.

[0034] The antibody titer can be calculated, for example, as U / mL (concentration of antibody against periodontal pathogenic bacteria in a blood sample).

[0035] As a reference value for comparison with the antibody titer against periodontal pathogenic bacteria in a blood sample collected from a subject, for example, the blood antibody titer can be set to 100 U / mL or the like.

[0036] The stratification method of the present disclosure may further include comparing the age of the subject with a reference value and classifying the subject into a group equal to or greater than the reference value or a group less than the reference value. For example, for a subject classified into a group with an antibody titer equal to or greater than the reference value, the age of the subject may be compared with the reference value, and the subject may be classified into a group equal to or greater than the reference value or a group less than the reference value.

[0037] As a reference value for comparison with the age of the subject, for example, it can be set to 40 years old, 50 years old, or the like. Preferably, it is 40 years old.

[0038] The stratification method of the present disclosure can classify a subject into a group with plaque adhesion and an antibody titer equal to or greater than the reference value; a group with plaque adhesion and an antibody titer less than the reference value; a group without plaque adhesion and an antibody titer equal to or greater than the reference value; or a group without plaque adhesion and an antibody titer less than the reference value.

[0039] In addition, the stratification method of the present disclosure classifies subjects into the following groups: a group with plaque attachment, antibody titer equal to or higher than the reference value, and age equal to or higher than the reference value; a group with plaque attachment, antibody titer equal to or higher than the reference value, and age less than the reference value; a group with plaque attachment, antibody titer less than the reference value, and age equal to or higher than the reference value; a group with plaque attachment, antibody titer less than the reference value, and age less than the reference value; a group without plaque attachment, antibody titer equal to or higher than the reference value, and age equal to or higher than the reference value; a group without plaque attachment, antibody titer equal to or higher than the reference value, and age less than the reference value; a group without plaque attachment, antibody titer less than the reference value, and age equal to or higher than the reference value; or a group without plaque attachment, antibody titer less than the reference value, and age less than the reference value.

[0040] According to the stratification method of the present disclosure, subjects can be stratified according to the presence or absence and degree of periodontal disease.

[0041] Periodontal disease is roughly classified into gingivitis and periodontitis (mild periodontitis, severe periodontitis). In this specification, "gingivitis" means a state in which plaque accumulates on the gingival margin and inflammation of the gingiva causes swelling and bleeding. In this specification, "periodontitis" means a state in which gingivitis further progresses, plaque accumulates subgingivally, alveolar bone is destroyed, the gap between the tooth and the tooth stem deepens, and a periodontal pocket is formed. In this specification, when the depth of the periodontal pocket is 4 mm or more and less than 6 mm, it is defined as "mild periodontitis", and when the depth of the periodontal pocket is 6 mm or more, it is defined as "severe periodontitis".

[0042] According to the stratification method of the present disclosure, even when a dental expert is absent or a dental check-up has not been performed, based on, for example, the results of blood tests and other examinations in a health check-up and oral images taken, subjects can be stratified according to the presence or absence and degree of periodontal disease based on the presence or absence of plaque attachment and the antibody titer against periodontal pathogenic bacteria in a blood sample.

[0043] As shown in the examples described below, when there is plaque adhesion, the proportion of subjects without periodontal disease is low, and the proportion of subjects with gingivitis and mild periodontitis is high. Therefore, it is considered that plaque adhesion is involved in the onset of periodontal disease (occurrence of inflammation). Also, as shown in the examples described below, when the antibody titer is high, the proportion of subjects with gingivitis is low, and the proportion of subjects with periodontitis (mild periodontitis and severe periodontitis) is high. Therefore, the antibody titer against periodontal pathogens in the blood sample is considered to be involved in the exacerbation of periodontal disease.

[0044] According to the stratification method of the present disclosure, the group with plaque adhesion and an antibody titer equal to or higher than the reference value has a higher proportion of subjects with periodontitis (especially severe periodontitis) compared to other groups. Also, the group with plaque adhesion and an antibody titer equal to or higher than the reference value has a lower proportion of subjects with gingivitis compared to other groups (more specifically, the group with plaque adhesion and an antibody titer lower than the reference value). Therefore, according to the stratification method of the present disclosure, it can be predicted (determined) that the subjects classified into the group with plaque adhesion and an antibody titer equal to or higher than the reference value are more likely to have periodontitis (especially severe periodontitis) compared to the subjects classified into other groups. According to the stratification method of the present disclosure, the group with plaque adhesion and an antibody titer lower than the reference value has a higher proportion of subjects with gingivitis compared to other groups (more specifically, the group with plaque adhesion and an antibody titer equal to or higher than the reference value). Therefore, according to the stratification method of the present disclosure, it can be predicted (determined) that the subjects classified into the group with plaque adhesion and an antibody titer lower than the reference value are more likely to have gingivitis compared to the subjects classified into other groups. According to the stratification method of the present disclosure, the group without plaque adhesion and with antibody titer above the reference value has a higher proportion of subjects with periodontitis compared to other groups (more specifically, the group without plaque adhesion and with antibody titer below the reference value). Therefore, according to the stratification method of the present disclosure, it can be predicted (determined) that the subjects classified into the group without plaque adhesion and with antibody titer above the reference value are more likely to have periodontitis compared to the subjects classified into other groups (more specifically, the group without plaque adhesion and with antibody titer below the reference value). According to the stratification method of the present disclosure, in the group without plaque adhesion and with antibody titer below the reference value, the proportion of subjects without periodontal disease (healthy subjects) is high. Therefore, according to the stratification method of the present disclosure, it can be predicted (determined) that the subjects classified into the group without plaque adhesion and with antibody titer below the reference value are likely to be subjects without periodontal disease (healthy subjects).

[0045] According to the stratification method of the present disclosure, the group with plaque adhesion, antibody titer above the reference value, and age above the reference value has a higher proportion of subjects with periodontitis (especially severe periodontitis) compared to other groups. Also, the group with plaque adhesion, antibody titer above the reference value, and age above the reference value has a lower proportion of subjects with gingivitis compared to other groups (more specifically, the group with plaque adhesion and antibody titer below the reference value, and the group with plaque adhesion, antibody titer above the reference value, and age below the reference value). Therefore, according to the stratification method of the present disclosure, it can be predicted (determined) that the subjects classified into the group with plaque adhesion, antibody titer above the reference value, and age above the reference value are more likely to have periodontitis (especially severe periodontitis) compared to the subjects classified into other groups. According to the stratification method of the present disclosure, the group with plaque adhesion, antibody titer equal to or higher than the reference value, and age less than the reference value has a higher proportion of subjects with gingivitis compared to other groups (more specifically, the group with plaque adhesion, antibody titer equal to or higher than the reference value, and age equal to or higher than the reference value). Therefore, according to the stratification method of the present disclosure, a subject classified into the group with plaque adhesion, antibody titer equal to or higher than the reference value, and age less than the reference value can be predicted (judged) to have a higher possibility of having gingivitis compared to a subject classified into other groups (more specifically, the group with plaque adhesion, antibody titer equal to or higher than the reference value, and age equal to or higher than the reference value). According to the stratification method of the present disclosure, the group with no plaque adhesion, antibody titer equal to or higher than the reference value, and age equal to or higher than the reference value has a higher proportion of subjects with periodontitis compared to other groups (more specifically, the group with no plaque adhesion and antibody titer less than the reference value, and the group with no plaque adhesion, antibody titer equal to or higher than the reference value, and age less than the reference value). Therefore, according to the stratification method of the present disclosure, a subject classified into the group with no plaque adhesion, antibody titer equal to or higher than the reference value, and age equal to or higher than the reference value can be predicted (judged) to have a higher possibility of having periodontitis compared to a subject classified into other groups (more specifically, the group with no plaque adhesion and antibody titer less than the reference value, and the group with no plaque adhesion, antibody titer equal to or higher than the reference value, and age less than the reference value). According to the stratification method of the present disclosure, the group with no plaque adhesion, antibody titer equal to or higher than the reference value, and age less than the reference value has a higher proportion of subjects without periodontal disease (healthy subjects). Therefore, according to the stratification method of the present disclosure, a subject classified into the group with no plaque adhesion, antibody titer equal to or higher than the reference value, and age less than the reference value can be predicted (judged) to have a higher possibility of being a subject without periodontal disease (healthy subject).

[0046] According to the present disclosure, for example, even a subject classified into the group with no plaque adhesion can be predicted (judged) to be a subject suffering from periodontal disease or a subject with a high degree of its prevalence. For example, as shown in the examples described later, even if there is no plaque adhesion, when the antibody titer against periodontal pathogenic bacteria is equal to or higher than the reference value, it is possible to predict (determine) that there may be periodontitis. Also, for example, as shown in the examples described later, even if there is no plaque adhesion, when the antibody titer against periodontal pathogenic bacteria is equal to or higher than the reference value and the age of the subject is equal to or higher than the reference value, it is possible to predict (determine) that there may be periodontitis. By using the age as the reference value, it is expected that the subjects can be stratified more accurately according to the presence or absence or the degree of periodontal disease.

[0047] According to the present disclosure, for example, even in the case of a subject classified into a group with an antibody titer against periodontal pathogenic bacteria equal to or higher than the reference value, it is possible to predict (determine) a subject who does not have periodontal disease (a healthy subject). For example, as shown in the examples described later, even if the antibody titer against periodontal pathogenic bacteria is equal to or higher than the reference value, when there is no plaque adhesion, it is possible to predict (determine) that the subject is likely to be a subject who does not have periodontal disease (a healthy subject). Also, for example, as shown in the examples described later, even if the antibody titer against periodontal pathogenic bacteria is equal to or higher than the reference value, when there is no plaque adhesion and the age of the subject is less than the reference value, it is possible to predict (determine) that the subject is likely to be a subject who does not have periodontal disease (a healthy subject). By using the age as the reference value, it is expected that the subjects can be stratified more accurately according to the presence or absence or the degree of periodontal disease.

[0048] According to the stratification method of the present disclosure, the subjects can be stratified according to the presence or absence or the degree of periodontal disease. Therefore, the stratification method of the present disclosure can be suitably used for determining an oral hygiene product or an oral hygiene method suitable for the subject.

[0049] Examples of oral hygiene products include toothbrushes, interdental cleaners, ointments, pastes, pastas, gels, liquids, sprays, mouthwashes, liquid dentifrices, chewing dentifrices, gums, tablets, troches, drops, films, toothbrushing log devices for recording the number of toothbrushing times or toothbrushing duration, light irradiation devices for sterilizing periodontal pathogenic bacteria, and the like. The oral hygiene products may be pharmaceuticals, quasi-drugs, foods, or the like. Examples of oral hygiene methods include toothbrushing methods and optimal usage methods of oral hygiene products. Although not particularly limited, more specifically, for example, the time for one toothbrushing (brushing) is set to 3 minutes or more, the number of toothbrushing times per day is set to 3 times or more, all teeth are evenly brushed to every corner, the size selection and usage method of interdental cleaners, and the like.

[0050] According to the present disclosure, it is possible to provide an oral hygiene product or an oral hygiene method suitable for a stratified subject. According to the present disclosure, for example, it is possible to provide an oral hygiene product or an oral hygiene method for a subject classified into a group with plaque adhesion. According to the present disclosure, for example, it is possible to provide an oral hygiene product or an oral hygiene method for a subject classified into a group without plaque adhesion. According to the present disclosure, for example, it is possible to provide an oral hygiene product or an oral hygiene method for a subject classified into a group with an antibody titer equal to or higher than a reference value. According to the present disclosure, for example, it is possible to provide an oral hygiene product or an oral hygiene method for a subject classified into a group with an antibody titer less than a reference value. According to the present disclosure, for example, it is possible to provide an oral hygiene product or an oral hygiene method for a subject classified into a group with plaque adhesion and an antibody titer equal to or higher than a reference value. According to the present disclosure, for example, it is possible to provide an oral hygiene product or an oral hygiene method for a subject classified into a group with plaque adhesion and an antibody titer less than a reference value. According to the present disclosure, for example, an oral hygiene product or an oral hygiene method for a subject classified into a group having no plaque adhesion and an antibody titer equal to or higher than a reference value can be provided. According to the present disclosure, for example, an oral hygiene product or an oral hygiene method for a subject classified into a group having no plaque adhesion and an antibody titer less than a reference value can be provided.

[0051] Further, according to the present disclosure, for example, an oral hygiene product or an oral hygiene method for a subject classified into a group having plaque adhesion, an antibody titer equal to or higher than a reference value, and an age equal to or higher than a reference value can be provided. According to the present disclosure, for example, an oral hygiene product or an oral hygiene method for a subject classified into a group having plaque adhesion, an antibody titer equal to or higher than a reference value, and an age less than a reference value can be provided. According to the present disclosure, for example, an oral hygiene product or an oral hygiene method for a subject classified into a group having plaque adhesion, an antibody titer less than a reference value, and an age equal to or higher than a reference value can be provided. According to the present disclosure, for example, an oral hygiene product or an oral hygiene method for a subject classified into a group having plaque adhesion, an antibody titer less than a reference value, and an age less than a reference value can be provided. According to the present disclosure, for example, an oral hygiene product or an oral hygiene method for a subject classified into a group having no plaque adhesion, an antibody titer equal to or higher than a reference value, and an age equal to or higher than a reference value can be provided. According to the present disclosure, for example, an oral hygiene product or an oral hygiene method for a subject classified into a group having no plaque adhesion, an antibody titer equal to or higher than a reference value, and an age less than a reference value can be provided. According to the present disclosure, for example, an oral hygiene product or an oral hygiene method for a subject classified into a group having no plaque adhesion, an antibody titer less than a reference value, and an age equal to or higher than a reference value can be provided. According to the present disclosure, for example, an oral hygiene product or an oral hygiene method for a subject classified into a group having no plaque adhesion, an antibody titer less than a reference value, and an age less than a reference value can be provided.

[0052] Oral hygiene products may be, for example, for reducing plaque, suppressing plaque formation, killing periodontal pathogenic bacteria, suppressing the growth of periodontal pathogenic bacteria, suppressing the colonization of periodontal pathogenic bacteria, preventing the colonization of periodontal pathogenic bacteria, etc.

[0053] For subjects classified into the group with plaque adhesion, for example, reducing plaque, suppressing plaque formation, etc. are presumed to be effective for suppressing inflammation. As a means of reducing plaque, improvement of mechanical plaque removal (increasing the number of toothbrushing times, using interdental cleaning tools, etc.) is presumed to be particularly effective. For subjects classified into the group without plaque adhesion and with an antibody titer against periodontal pathogenic bacteria below the reference value, for example, maintaining the quality of plaque in a good state, suppressing the colonization of periodontal pathogenic bacteria, preventing the colonization of periodontal pathogenic bacteria, etc. are presumed to be effective for preventing periodontal disease. Even for subjects classified into the group without plaque adhesion, for subjects classified into the group with an antibody titer against periodontal pathogenic bacteria above the reference value, for example, killing periodontal pathogenic bacteria, suppressing the growth of periodontal pathogenic bacteria, preventing the invasion of periodontal pathogenic bacteria into gingival cells, etc. are presumed to be effective for suppressing the progression of periodontal disease.

[0054] As oral hygiene products for subjects classified into the group with plaque adhesion, for example, those for reducing plaque, suppressing plaque formation, etc. may be used. As oral hygiene products for subjects classified into the group without plaque adhesion, for example, those for killing periodontal pathogenic bacteria, suppressing the growth of periodontal pathogenic bacteria, suppressing the colonization of periodontal pathogenic bacteria, preventing the colonization of periodontal pathogenic bacteria, etc. may be used. As oral hygiene products for subjects classified into the group with an antibody titer above the reference value, for example, those for killing periodontal pathogenic bacteria, suppressing the growth of periodontal pathogenic bacteria, inhibiting the invasion of periodontal pathogenic bacteria into gingival cells, etc. may be used. As oral hygiene products for subjects classified into the group with an antibody titer below the reference value, for example, those for suppressing the colonization of periodontal pathogenic bacteria, preventing the colonization of periodontal pathogenic bacteria, maintaining the oral flora, etc. may be used. For subjects classified into the group with plaque adhesion and antibody titer equal to or higher than the reference value, oral hygiene products may include, for example, those for reducing plaque, suppressing plaque formation, killing periodontal pathogenic bacteria, suppressing the growth of periodontal pathogenic bacteria, etc. For subjects classified into the group with plaque adhesion and antibody titer less than the reference value, oral hygiene products may include, for example, those for reducing plaque, suppressing plaque formation, suppressing the colonization of periodontal pathogenic bacteria, preventing the colonization of periodontal pathogenic bacteria, etc. For subjects classified into the group without plaque adhesion and antibody titer equal to or higher than the reference value, oral hygiene products may include, for example, those for suppressing plaque formation, killing periodontal pathogenic bacteria, suppressing the growth of periodontal pathogenic bacteria, etc. For subjects classified into the group without plaque adhesion and antibody titer less than the reference value, oral hygiene products may include, for example, those for suppressing plaque formation, suppressing the colonization of periodontal pathogenic bacteria, preventing the colonization of periodontal pathogenic bacteria, etc. For subjects classified into the group with plaque adhesion, antibody titer equal to or higher than the reference value, and age equal to or higher than the reference value, oral hygiene products may include, for example, those for reducing plaque, suppressing plaque formation, killing periodontal pathogenic bacteria, suppressing the growth of periodontal pathogenic bacteria, inhibiting the invasion of periodontal pathogenic bacteria into gingival cells, etc. For subjects classified into the group with plaque adhesion, antibody titer equal to or higher than the reference value, and age less than the reference value, oral hygiene products may include, for example, those for reducing plaque, suppressing plaque formation, suppressing the colonization of periodontal pathogenic bacteria, preventing the colonization of periodontal pathogenic bacteria, etc. For subjects classified into the group without plaque adhesion, antibody titer equal to or higher than the reference value, and age equal to or higher than the reference value, oral hygiene products may include, for example, those for killing periodontal pathogenic bacteria, suppressing the growth of periodontal pathogenic bacteria, etc. For subjects classified into the group without plaque adhesion, antibody titer equal to or higher than the reference value, and age less than the reference value, oral hygiene products may include, for example, those for suppressing the colonization of periodontal pathogenic bacteria, preventing the colonization of periodontal pathogenic bacteria, etc.

[0055] The present disclosure can provide a program for implementing the above-described stratification method of the present disclosure. That is, the program causes a computer to have a first function of obtaining the presence or absence of plaque adhesion of a subject and the antibody titer against periodontal pathogenic bacteria in a blood sample, and a second function of stratifying the subject based on the presence or absence of plaque adhesion and the antibody titer against periodontal pathogenic bacteria in the blood sample obtained by the first function.

[0056] Regarding the presence or absence of plaque adhesion, the antibody titer against periodontal pathogenic bacteria in the blood sample, and the stratification of the subject based on the presence or absence of plaque adhesion and the antibody titer, the above-described description can be incorporated by reference.

[0057] The stratification result can be provided to the subject via a network, for example. Also, for example, oral hygiene products or oral hygiene methods for the subjects classified into the above-described groups can be presented to the subject via a network. For example, information such as the stratification result, oral hygiene products, or oral hygiene methods can be transmitted to the subject's smartphone, tablet terminal, etc. Also, for example, based on the stratification result, proposals, guidance, etc. on oral hygiene products or oral hygiene methods can be provided to the subject via a network.

[0058] The present disclosure also includes a method for measuring (predicting) the presence or absence or degree of periodontal disease in a subject. In this specification, this method may be referred to as "the method for measuring the presence or absence or degree of periodontal disease of the present disclosure".

[0059] The method for measuring the presence or absence or degree of periodontal disease of the present disclosure preferably uses the presence or absence of plaque adhesion of the subject and the antibody titer against periodontal pathogenic bacteria in a blood sample as indicators. The method for measuring the presence or absence or degree of periodontal disease of the present disclosure may further use age as an indicator.

[0060] The method for measuring the presence or absence or degree of periodontal disease according to the present disclosure preferably includes stratifying subjects based on the presence or absence of plaque adhesion and antibody titer. The method for measuring the presence or absence or degree of periodontal disease according to the present disclosure may further include stratifying subjects based on age.

[0061] Regarding the presence or absence of plaque adhesion, the antibody titer against periodontal pathogenic bacteria in a blood sample, and the method for stratifying subjects based on the presence or absence of plaque adhesion and antibody titer, etc., the description of the "stratification method according to the present disclosure" described above can be incorporated by reference.

[0062] According to the method for measuring the presence or absence or degree of periodontal disease according to the present disclosure, based on the stratification result, the presence or absence or degree of periodontal disease of the subject can be measured (predicted).

[0063] The present disclosure can provide a program for realizing the method for measuring the presence or absence or degree of periodontal disease according to the present disclosure described above. That is, the program causes a computer to have a first function of acquiring the presence or absence of plaque adhesion of a subject and the antibody titer against periodontal pathogenic bacteria in a blood sample, a second function of stratifying the subject based on the presence or absence of plaque adhesion and the antibody titer against periodontal pathogenic bacteria in a blood sample acquired by the first function, and a third function of measuring (predicting) the presence or absence or degree of periodontal disease of the subject based on the stratification result.

[0064] The present disclosure also includes a method for assisting in the stratification of subjects according to the presence or absence or degree of periodontal disease. In this specification, this method may be referred to as the "method for assisting stratification according to the present disclosure".

[0065] The method for assisting stratification according to the present disclosure preferably uses the presence or absence of plaque adhesion of the subject and the antibody titer against periodontal pathogenic bacteria in a blood sample as indicators. The method for assisting stratification according to the present disclosure may further use age as an indicator.

[0066] The method for assisting stratification of the present disclosure preferably includes stratifying a subject based on the presence or absence of plaque adhesion and antibody titer. The method for assisting stratification of the present disclosure may further include stratifying a subject based on age.

[0067] Regarding the presence or absence of plaque adhesion, the antibody titer against periodontal pathogenic bacteria in a blood sample, and the method for stratifying a subject based on the presence or absence of plaque adhesion and antibody titer, etc., the description of the "stratification method of the present disclosure" described above can be incorporated by reference.

[0068] According to the method for assisting stratification of the present disclosure, it is possible to assist in stratifying a subject according to the presence or absence or degree of periodontal disease.

[0069] The present disclosure can provide a program for realizing the method for assisting stratification of the present disclosure described above. That is, the program causes a computer to have a first function of obtaining the presence or absence of plaque adhesion of a subject and the antibody titer against periodontal pathogenic bacteria in a blood sample, and based on the presence or absence of plaque adhesion and the antibody titer against periodontal pathogenic bacteria in a blood sample obtained by the first function, it is a program for realizing a second function of stratifying a subject.

[0070] The present disclosure also includes a method for assisting in determining (diagnosing) the presence or absence or degree of periodontal disease in a subject. In this specification, this method may be referred to as the "method for assisting in determining the presence or absence or degree of periodontal disease of the present disclosure".

[0071] The method for assisting in determining the presence or absence or degree of periodontal disease of the present disclosure preferably uses the presence or absence of plaque adhesion of a subject and the antibody titer against periodontal pathogenic bacteria in a blood sample as indicators. The method for assisting in determining the presence or absence or degree of periodontal disease of the present disclosure may further use age as an indicator.

[0072] The method for assisting in determining the presence or absence or degree of periodontal disease according to the present disclosure preferably includes stratifying subjects based on the presence or absence of plaque adhesion and antibody titer. The method for assisting in determining the presence or absence or degree of periodontal disease according to the present disclosure may further include stratifying subjects based on age.

[0073] Regarding the presence or absence of plaque adhesion, the antibody titer against periodontal pathogenic bacteria in a blood sample, and the method of stratifying subjects based on the presence or absence of plaque adhesion and antibody titer, etc., the description of the "stratification method of the present disclosure" described above can be incorporated by reference.

[0074] According to the method for assisting in determining the presence or absence or degree of periodontal disease according to the present disclosure, based on the stratification result, it is possible to assist in determining the presence or absence or degree of periodontal disease of the subject.

[0075] The present disclosure can provide a program for realizing the method for assisting in determining the presence or absence or degree of periodontal disease according to the present disclosure described above. That is, the program causes a computer to have a first function of acquiring the presence or absence of plaque adhesion of a subject and the antibody titer against periodontal pathogenic bacteria in a blood sample, and based on the presence or absence of plaque adhesion and the antibody titer against periodontal pathogenic bacteria in a blood sample acquired by the first function, a second function of stratifying the subject, and a third function of determining the presence or absence or degree of periodontal disease of the subject based on the stratification result.

[0076] The present disclosure also includes a method for measuring (predicting) the risk of onset or exacerbation of periodontal disease in a subject. In this specification, this method may be referred to as the "method for measuring the risk of onset or exacerbation of periodontal disease according to the present disclosure".

[0077] The method for measuring the risk of onset or exacerbation of periodontal disease according to the present disclosure preferably uses the presence or absence of plaque adhesion of the subject and the antibody titer against periodontal pathogenic bacteria in a blood sample as indicators. The method for measuring the risk of onset or exacerbation of periodontal disease according to the present disclosure may further use age as an indicator.

[0078] The method for measuring the risk of onset or exacerbation of periodontal disease according to the present disclosure preferably includes stratifying the subject based on the presence or absence of plaque adhesion and antibody titer. The method for measuring the risk of onset or exacerbation of periodontal disease according to the present disclosure may further include stratifying the subject based on age.

[0079] Regarding the presence or absence of plaque adhesion, the antibody titer against periodontal pathogenic bacteria in a blood sample, and the method for stratifying the subject based on the presence or absence of plaque adhesion and antibody titer, etc., the description of the "stratification method of the present disclosure" described above can be incorporated by reference.

[0080] According to the method for measuring the risk of onset or exacerbation of periodontal disease according to the present disclosure, based on the stratification result, the risk of onset or exacerbation of periodontal disease in the subject can be measured (predicted).

[0081] The present disclosure can provide a program for realizing the method for measuring the risk of onset or exacerbation of periodontal disease according to the present disclosure described above. That is, the program causes a computer to have a first function of obtaining the presence or absence of plaque adhesion of the subject and the antibody titer against periodontal pathogenic bacteria in a blood sample, and based on the presence or absence of plaque adhesion and the antibody titer against periodontal pathogenic bacteria in a blood sample obtained by the first function, a second function of stratifying the subject, and based on the stratification result, a third function of measuring (predicting) the risk of onset or exacerbation of periodontal disease in the subject.

[0082] The present disclosure also includes a method for assisting in determining the risk of onset or exacerbation of periodontal disease in a subject. In this specification, this method may be referred to as "a method for assisting in determining the risk of onset or exacerbation of periodontal disease according to the present disclosure".

[0083] A method for assisting in determining the risk of onset or exacerbation of periodontal disease according to the present disclosure preferably uses the presence or absence of plaque attachment in a subject and the antibody titer against periodontal pathogenic bacteria in a blood sample as indicators. The method for assisting in determining the risk of onset or exacerbation of periodontal disease according to the present disclosure may further use age as an indicator.

[0084] A method for assisting in determining the risk of onset or exacerbation of periodontal disease according to the present disclosure preferably includes stratifying the subject based on the presence or absence of plaque attachment and the antibody titer. The method for assisting in determining the risk of onset or exacerbation of periodontal disease according to the present disclosure may further include stratifying the subject based on age.

[0085] Regarding the presence or absence of plaque attachment, the antibody titer against periodontal pathogenic bacteria in a blood sample, and the method of stratifying the subject based on the presence or absence of plaque attachment and the antibody titer, etc., the description of the "stratification method according to the present disclosure" described above can be incorporated by reference.

[0086] According to the method for assisting in determining the risk of onset or exacerbation of periodontal disease according to the present disclosure, based on the stratification result, it is possible to assist in determining the risk of onset or exacerbation of periodontal disease in the subject.

[0087] The present disclosure can provide a program for realizing the method for assisting in determining the risk of onset or exacerbation of periodontal disease according to the present disclosure described above. That is, the program causes a computer to have a first function of acquiring the presence or absence of plaque attachment in a subject and the antibody titer against periodontal pathogenic bacteria in a blood sample, a second function of stratifying the subject based on the presence or absence of plaque attachment and the antibody titer acquired by the first function, and a third function of determining the risk of onset or exacerbation of periodontal disease in the subject based on the stratification result.

[0088] The present disclosure also includes a method for assisting in determining (presenting) an oral hygiene product or an oral hygiene method suitable for a subject according to the presence or absence or degree of periodontal disease in the subject. In the present specification, this method may be referred to as "a method for assisting in determining an oral hygiene product or an oral hygiene method of the present disclosure".

[0089] The method for assisting in determining an oral hygiene product or an oral hygiene method of the present disclosure preferably uses the presence or absence of plaque adhesion in the subject and the antibody titer against periodontal pathogens in a blood sample as indicators. The method for assisting in determining an oral hygiene product or an oral hygiene method of the present disclosure may further use age as an indicator.

[0090] The method for assisting in determining an oral hygiene product or an oral hygiene method of the present disclosure preferably includes stratifying the subject based on the presence or absence of plaque adhesion and the antibody titer. The method for assisting in determining an oral hygiene product or an oral hygiene method of the present disclosure may further include stratifying the subject based on age.

[0091] Regarding the presence or absence of plaque adhesion, the antibody titer against periodontal pathogens in a blood sample, and the method of stratifying the subject based on the presence or absence of plaque adhesion and the antibody titer, etc., the description of the "stratification method of the present disclosure" described above can be incorporated by reference.

[0092] According to the method for assisting in determining an oral hygiene product or an oral hygiene method of the present disclosure, based on the stratification result, it is possible to assist in determining (presenting) an oral hygiene product or an oral hygiene method suitable for the subject.

[0093] The present disclosure can provide a program for realizing a method for assisting in determining the oral hygiene product or oral hygiene method of the present disclosure described above. That is, the program causes a computer to have a first function of acquiring the presence or absence of plaque adhesion of a subject and the antibody titer against periodontal pathogenic bacteria in a blood sample, and based on the presence or absence of plaque adhesion acquired by the first function and the antibody titer against periodontal pathogenic bacteria in the blood sample, a second function of stratifying the subject, and a third function of determining (presenting) an oral hygiene product or oral hygiene method suitable for the subject based on the stratification result.

[0094] In addition, in this specification, "comprising" includes "consisting essentially of" and "consisting of". Further, the present disclosure includes all arbitrary combinations of the constituent elements described in this specification.

[0095] Moreover, the various characteristics (properties, structures, functions, etc.) described for each embodiment of the present disclosure above may be combined in any manner when specifying the subject matter included in the present disclosure. That is, the present disclosure includes all subject matters consisting of all possible combinations of the combinable characteristics described in this specification.

Example

[0096] The content of the present disclosure will be specifically described using the following test examples. However, the present disclosure is not limited to these in any way. In the following, unless otherwise specifically mentioned, the experiments are carried out under atmospheric pressure and normal temperature conditions.

[0097] Regarding 588 subjects (398 males and 190 females (average age 45.2 years old)), the following items were confirmed according to the described methods respectively.

[0098] Test Example 1 Presence or absence of plaque (measurement of PlI (Plaque Index)) The PlI was measured for six representative teeth per person (Figure 1). The representative teeth were the upper right 6, upper right 1, upper left 6, lower right 6, lower left 1, and lower left 6. However, when 6 was missing, the measurement was taken using 7. PlI is an index indicating the degree of plaque adhesion. The PlI was measured for six representative teeth according to the following criteria. The value of the most adherent part (maximum value) in one tooth was adopted. <Criteria> 0: No adhesion was observed 1: Plaque adhesion less than 1 / 3 of the tooth surface 2: Plaque adhesion of 1 / 3 or more and less than 2 / 3 of the tooth surface 3: Plaque adhesion of 2 / 3 or more of the tooth surface The average value was calculated from the PlI of six representative teeth. When the average value of PlI was 0, it was regarded as "no plaque", and when the average value of PlI was greater than 0, it was regarded as "plaque present".

[0099] Test Example 2 Blood antibody titer Using the antigen protein 35N (SEQ ID NO: 1) having a GST tag on the N-terminal side as an antigen, the measurement was performed by the CLEIA method (more specifically, the method described in Japanese Patent No. 6716241).

[0100] An ALP-labeled antigen and a biotin-labeled antigen were prepared. A serum specimen of a subject was mixed with a solution containing the ALP-labeled antigen and a solution containing the biotin-labeled antigen to prepare a complex of an antibody against periodontal pathogenic bacteria contained in the biological sample, the ALP-labeled antigen, and the biotin-labeled antigen. The complex was contacted with a porous carrier carrying an anti-biotin antibody to bind the complex to the porous carrier, and the chemiluminescence intensity (40 °C, 1 minute) obtained by adding the substrate of ALP was measured. A calibration curve was prepared using a standard positive serum with a clear antibody concentration against periodontal pathogenic bacteria, and the antibody titer (U / mL) was calculated. The cut-off value of the antibody titer in blood was set at 100 U / mL, and it was classified into a group of 100 U / mL or more or a group of less than 100 U / mL.

[0101] Test Example 3 Classification of periodontal disease The CPI (Community Periodontal Index) was measured by a dental expert's examination. <Reference> Code 0: Sound Code 1: Bleeding Code 2: Calculus deposition Code 3: Shallow periodontal pocket (PD = 4 - 5 mm) Code 4: Deep periodontal pocket (PD ≥ 6 mm) The codes of the representative teeth were measured respectively, and the maximum code was taken as the representative value of each subject. By combining Codes 1 and 2 as gingivitis, each subject was classified into the following 4 groups.

[0102]

Table 1

[0103] 1. Classification by the presence or absence of plaque The classification results of periodontal diseases in the groups with and without plaque attachment are shown below.

[0104]

Table 2

[0105] In the group with plaque attachment, it was confirmed that the proportion of subjects with gingivitis or periodontitis was high. On the other hand, even in the group without plaque attachment, about 24% of the subjects had periodontitis. Therefore, it was found that the presence or absence of periodontal disease or its degree could not be predicted only by the presence or absence of plaque attachment (there is a possibility of missing subjects at risk of periodontal disease).

[0106] 2. Classification by the presence or absence of plaque and antibody titer After classifying into the groups with and without plaque attachment, they were further classified into the groups with a blood antibody titer of 100 U / mL or more and the groups with a blood antibody titer of less than 100 U / mL. The classification results of periodontal diseases in each group are shown below.

[0107]

Table 3

[0108] Even in the group without plaque adhesion, in the group with an antibody titer of 100 U / mL or more, it was confirmed that the proportion of subjects with periodontitis was higher compared to the group with less than 100 U / mL. Also, in the group with plaque adhesion, in the group with an antibody titer of 100 U / mL or more, the proportion of subjects with periodontitis (especially severe periodontitis) was higher compared to other groups, and in the group with an antibody titer of less than 100 U / mL, the proportion of subjects with gingivitis was higher compared to other groups. Furthermore, when compared with the case of classification only by the presence or absence of plaque ([Table 2]), in the group with plaque adhesion and an antibody titer of 100 U / mL or more, it was confirmed that the proportion of subjects with gingivitis decreased and the proportion of subjects with periodontitis increased. Also, when there is plaque adhesion, the proportion of subjects without periodontal disease is low, and the proportion of subjects with gingivitis and mild periodontitis is high. Therefore, it is considered that plaque adhesion is involved in the onset (occurrence of inflammation) of periodontal disease. Also, when the antibody titer is high, the proportion of subjects with gingivitis is low, and the proportion of subjects with mild periodontitis and severe periodontitis is high. Therefore, it is considered that the antibody titer against periodontal pathogenic bacteria in the blood sample is involved in the exacerbation of periodontal disease. From the above, it is suggested that by classifying in combination with the presence or absence of plaque adhesion and the antibody titer, it is possible to predict the presence or absence or the degree of periodontal disease more accurately compared to the case of classification only by the presence or absence of plaque adhesion. It is suggested that the combination of the presence or absence of plaque adhesion and the antibody titer is an effective evaluation index for predicting the presence or absence or the degree of periodontal disease.

[0109] 3. Classification by the presence or absence of plaque, antibody titer, and age After classifying into the group with plaque adhesion and the group without it, it was further classified into the group with a blood antibody titer of 100 U / mL or more and the group with less than 100 U / mL, and in the group with a blood antibody titer of 100 U / mL or more, it was further classified into the group with an age of 40 years or more and the group with less than 40 years. The classification results of periodontal disease in each group are shown below.

[0110]

Table 4

[0111] Even in the group without plaque attachment, in the group with an antibody titer of 100 U / mL or more and an age of 40 years or older, it was confirmed that the proportion of subjects with periodontitis was higher compared to the group with an antibody titer of 100 U / mL or more and an age of less than 40 years. Furthermore, when compared with the case of classification by combining plaque attachment and antibody titer ([Table 3]), in the group without plaque attachment, with an antibody titer of 100 U / mL or more, and an age of less than 40 years, it was confirmed that the proportion of subjects with gingivitis and periodontitis decreased, and the proportion of subjects without periodontal disease increased. Also, in the group with plaque attachment, in the group with an antibody titer of 100 U / mL or more and an age of 40 years or older, it was confirmed that the proportion of subjects with periodontitis (especially severe periodontitis) was higher compared to the group with an antibody titer of 100 U / mL or more and an age of less than 40 years. Furthermore, when compared with the case of classification by combining plaque attachment and antibody titer ([Table 3]), in the group with plaque attachment, with an antibody titer of 100 U / mL or more, and an age of 40 years or older, it was confirmed that the proportion of subjects with gingivitis decreased, and the proportion of subjects with periodontitis increased. From the above, it was suggested that by classifying in combination with the presence or absence of plaque attachment, antibody titer, and age, it is possible to predict the presence or absence or degree of periodontal disease more accurately compared to classifying only by the presence or absence of plaque attachment or by combining plaque attachment and antibody titer. It was suggested that the combination of the presence or absence of plaque attachment, antibody titer, and age is a more effective evaluation index for predicting the presence or absence or degree of periodontal disease.

[0112] 4. Classification by the Presence or Absence of Plaque, Antibody Titer, and Age After classifying into the group with plaque attachment and the group without plaque attachment, the subjects were further classified into the group with a blood antibody titer of 100 U / mL or more and the group with a blood antibody titer of less than 100 U / mL. In the group with a blood antibody titer of 100 U / mL or more, the subjects were further classified into the group of 50 years old or older and the group of less than 50 years old. The classification results of periodontal diseases in each group are shown below.

[0113]

Table 5

[0114] In the group without plaque attachment and with an antibody titer of 100 U / mL or more, when classified by age at 50 years old, compared with the case of classification at 40 years old ([Table 4]), the difference in the proportion of subjects with periodontitis between the group of 50 years old or older and the group of less than 50 years old became smaller (in the group of less than 50 years old, the proportion of subjects with mild periodontitis increased). This was confirmed. Also, in the group with plaque attachment and with an antibody titer of 100 U / mL or more, when classified by age at 50 years old, compared with the case of classification at 40 years old ([Table 4]), the difference in the proportion of subjects with gingivitis or periodontitis between the group of 50 years old or older and the group of less than 50 years old became smaller (in the group of less than 50 years old, the proportion of subjects with gingivitis decreased and the proportion of subjects with periodontitis increased). This was confirmed. In addition, when classified by age at 30 years old, the number of subjects with an antibody titer of 100 U / mL or more was small (less than 15%), suggesting that it was not appropriate as a classification criterion for age. From this, it was suggested that when using age as an index, by using 40 years old as a reference, the presence or absence or degree of periodontal disease can be predicted with higher accuracy.

Claims

1. A method for stratifying subjects, comprising: classifying the subjects into a group with plaque attachment or a group without plaque attachment, and comparing the antibody titer against periodontal pathogens in a blood sample collected from the subject with a reference value, and classifying the subject into a group with a value equal to or higher than the reference value or a group with a value lower than the reference value and suggesting that subjects with plaque attachment and an antibody titer equal to or higher than the reference value are highly likely to have severe periodontitis, suggesting that subjects with plaque attachment and an antibody titer lower than the reference value are highly likely to have gingivitis, suggesting that subjects without plaque attachment and an antibody titer equal to or higher than the reference value are highly likely to have periodontitis, and suggesting that subjects without plaque attachment and an antibody titer lower than the reference value are highly likely not to have periodontal disease.

2. A method for stratifying subjects, comprising: classifying the subjects into a group with plaque attachment or a group without plaque attachment, comparing the antibody titer against periodontal pathogens in a blood sample collected from the subject with a reference value, and classifying the subject into a group with a value equal to or higher than the reference value or a group with a value lower than the reference value, and comparing the age of the subject with a reference value, and classifying the subject into a group with a value equal to or higher than the reference value or a group with a value lower than the reference value, suggesting that subjects with plaque attachment, an antibody titer equal to or higher than the reference value, and an age equal to or higher than the reference value are highly likely to have severe periodontitis, suggesting that subjects with plaque attachment, an antibody titer equal to or higher than the reference value, and an age lower than the reference value are highly likely to have gingivitis, suggesting that subjects without plaque attachment, an antibody titer equal to or higher than the reference value, and an age equal to or higher than the reference value are highly likely to have periodontitis, and A method characterized in that a subject without plaque adhesion, having an antibody titer equal to or higher than the reference value, and having an age less than the reference value is highly likely not to have periodontal disease.

3. The method according to claim 2, wherein the reference value of age is 40 years old.

4. The method according to any one of claims 1 to 3, characterized in that it is used to determine an oral hygiene product or an oral hygiene method suitable for the subject.

5. A method for determining an oral hygiene product suitable for a subject, comprising: classifying the subject into a group with plaque adhesion or a group without plaque adhesion, and comparing the antibody titer against periodontal pathogenic bacteria in a blood sample collected from the subject with a reference value, and classifying the subject into a group with a value equal to or higher than the reference value or a group with a value lower than the reference value including, and further determining that an oral hygiene product for improving severe periodontitis is a suitable oral hygiene product for a subject with plaque adhesion and an antibody titer equal to or higher than the reference value, determining that an oral hygiene product for improving gingivitis is a suitable oral hygiene product for a subject with plaque adhesion and an antibody titer lower than the reference value, determining that an oral hygiene product for improving periodontitis is a suitable oral hygiene product for a subject without plaque adhesion and an antibody titer equal to or higher than the reference value, and determining that an oral hygiene product for preventing periodontal disease is a suitable oral hygiene product for a subject without plaque adhesion and an antibody titer lower than the reference value, including.

6. A method for determining an oral hygiene product suitable for a subject, comprising: classifying the subject into a group with plaque adhesion or a group without plaque adhesion, comparing the antibody titer against periodontal pathogenic bacteria in a blood sample collected from the subject with a reference value, and classifying the subject into a group with a value equal to or higher than the reference value or a group with a value lower than the reference value, and Comparing the age of the subject with a reference value and classifying the subject into a group equal to or greater than the reference value or a group less than the reference value, and further, For subjects with plaque adhesion, an antibody titer equal to or greater than the reference value, and an age equal to or greater than the reference value, it is determined that an oral hygiene product for improving severe periodontitis is a suitable oral hygiene product. For subjects with plaque adhesion, an antibody titer equal to or greater than the reference value, and an age less than the reference value, it is determined that an oral hygiene product for improving gingivitis is a suitable oral hygiene product. For subjects without plaque adhesion, an antibody titer equal to or greater than the reference value, and an age equal to or greater than the reference value, it is determined that an oral hygiene product for improving periodontitis is a suitable oral hygiene product, and For subjects without plaque adhesion, an antibody titer equal to or greater than the reference value, and an age less than the reference value, it is determined that an oral hygiene product for preventing the onset of periodontal disease is a suitable oral hygiene product. A method comprising the above.

7. The method according to claim 6, wherein the reference value of age is 40 years old.

Images